Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

At the recent SEC meeting for analgesics and rheumatology held on February 25, 2025, the expert panel reviewed the ...

Q4 2024 Earnings Call Transcript March 20, 2025 Autolus Therapeutics plc beats earnings expectations. Reported EPS is $-0.09, ...

Madison Evans was 16 when she first felt the sharp pain in her lower pelvis, pain that radiated through her back and grew so ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Hello ladies and gentlemen and welcome to the Autolus Therapeutics call to discuss its full year 2024 financial results and business updates. As a reminder, this conference call is being recorded. I ...

In the updated diagnosis and classification system, originally proposed by the global Rosacea Consensus panel, two features ... of LL-37–induced IL-8 cytokine release, Bhatia pointed out.

Obstructive sleep apnea (OSA) and metabolic syndrome (MetS) are increasingly recognized as interrelated conditions with significant implications for ...

Moreover, cytokine priming enhances the anti-inflammatory and immunomodulatory ... cocultures were analyzed by flow cytometry using Human Essential Immune Response Panel (BioLegend, USA) according to ...

Multidisciplinary team including oversight and input from semi-independent BMJ Rapid Recommendation panel which includes patient and ... of the inflammatory cascade and upregulation of related ...